Literature DB >> 16842464

Predictors of treatment response in patients with non-erosive reflux disease.

N J Talley1, D Armstrong, O Junghard, I Wiklund.   

Abstract

BACKGROUND: Up to 40% of patients with non-erosive reflux disease (NERD) fail to respond to proton pump inhibitor therapy. AIM: To determine useful prognostic factors for response to and suppression in NERD.
METHODS: A pooled analysis from three multicentre, double-blind trials of patients with a normal endoscopy and heartburn for 4 days or more during the 7 days prior to the start of each treatment. Patients received omeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg/day for 4 weeks. Complete resolution of heartburn was defined as no heartburn during the last week.
RESULTS: Of 2458 patients included, complete heartburn resolution was achieved in 63% at the end of 4 weeks treatment. Response on days 5-7 provided an 85% probability of complete resolution of heartburn at 4 weeks; the probability of complete heartburn resolution at 4 weeks in those with moderate to severe symptoms on days 5-7 was 22%. Sensitivity and specificity of no heartburn on days 5-7 was 55% and 83% respectively. Patient demographics, duration of symptoms, medications used, other symptoms and body mass index were not predictors.
CONCLUSION: Assessment of heartburn resolution during the first week of therapy was the best predictor of treatment success at 4 weeks in non-erosive reflux disease, but was suboptimal as a test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842464     DOI: 10.1111/j.1365-2036.2006.02983.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease.

Authors:  Reginald V N Lord; Steven R DeMeester; Jeffrey H Peters; Jeffrey A Hagen; Dino Elyssnia; Corinne T Sheth; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2008-12-03       Impact factor: 3.452

Review 2.  Body mass index and the efficacy of acid-mediating agents for GERD.

Authors:  Brian C Jacobson
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

3.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

4.  Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.

Authors:  Robert C Heading; Hubert Mönnikes; Anne Tholen; Holger Schmitt
Journal:  BMC Gastroenterol       Date:  2011-05-11       Impact factor: 3.067

5.  The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

Authors:  D A Peura; B Pilmer; B Hunt; R Mody; M C Perez
Journal:  Aliment Pharmacol Ther       Date:  2013-03-04       Impact factor: 8.171

6.  The daily response for proton pump inhibitor treatment in Japanese reflux esophagitis and non-erosive reflux disease.

Authors:  Hiroshi Shida; Yuzo Sakai; Hiroyuki Hamada; Tetsuo Takayama
Journal:  J Clin Biochem Nutr       Date:  2012-11-13       Impact factor: 3.114

7.  Correlation between symptomatic improvement and quality of life in patients with reflux and dyspeptic symptoms.

Authors:  Seiji Arihiro; Tomohiro Kato; Kyoko Ito; Masayuki Saruta; Toshiki Nikami; Takeshi Suzuki; Hisao Tajiri
Journal:  J Clin Biochem Nutr       Date:  2011-12-07       Impact factor: 3.114

8.  Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.

Authors:  Khean Lee Goh; Kee Don Choi; Myung-Gyu Choi; Tsai-Yuan Hsieh; Hwoon-Yong Jung; Han-Chung Lien; Jayaram Menon; Steven Mesenas; Hyojin Park; Bor-Shyang Sheu; Justin Cy Wu
Journal:  BMC Gastroenterol       Date:  2014-09-09       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.